LSV Asset Management Increases Stock Holdings in Pacira BioSciences, Inc. $PCRX

LSV Asset Management increased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 179.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,800 shares of the company’s stock after purchasing an additional 205,500 shares during the period. LSV Asset Management’s holdings in Pacira BioSciences were worth $8,276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PCRX. Hantz Financial Services Inc. grew its position in Pacira BioSciences by 175.4% during the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after acquiring an additional 721 shares during the period. Global Retirement Partners LLC grew its position in Pacira BioSciences by 479.4% during the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after acquiring an additional 1,678 shares during the period. Tidemark LLC purchased a new stake in Pacira BioSciences during the third quarter valued at about $56,000. Strs Ohio purchased a new stake in Pacira BioSciences during the first quarter valued at about $75,000. Finally, Wolverine Asset Management LLC grew its position in Pacira BioSciences by 122.1% during the fourth quarter. Wolverine Asset Management LLC now owns 3,000 shares of the company’s stock valued at $78,000 after acquiring an additional 16,572 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Insider Activity

In related news, insider Jonathan Slonin sold 3,261 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the transaction, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Shawn Cross sold 12,941 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the completion of the transaction, the chief financial officer owned 105,341 shares in the company, valued at approximately $2,650,379.56. This trade represents a 10.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 28,261 shares of company stock worth $702,610. Insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Barclays lowered their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada boosted their price objective on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research note on Friday, May 1st. Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Finally, Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and a consensus target price of $29.40.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $23.35 on Tuesday. The stock’s 50-day moving average is $23.47 and its two-hundred day moving average is $23.28. The stock has a market cap of $918.82 million, a PE ratio of 194.60 and a beta of 0.32. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The business had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. During the same quarter last year, the firm posted $0.65 EPS. The company’s revenue was up 5.0% compared to the same quarter last year. Equities analysts forecast that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.